title: [Comparison on efficacy and safety between domestic levosimendan versus dobutamine for patients with acute decompensated heart failure].
abstract: OBJECTIVE
  To compare the efficacy and safety of domestic levosimendan versus dobutamine for patients with acute decompensated heart failure (ADHF).
  
  
  METHODS
  ADHF patients from 8 medical centers were recruited in this multicenter, blind, positive-controlled, randomized study and received 24 h intravenous levosimendan (n = 114) or dobutamine (n = 114) therapy. SWAN-GANZ catheter was performed in patients with pulmonary capillary wedge pressure (PCWP) ≥ 15 mm Hg (1 mm Hg = 0.133 kPa) and cardiac index (CI) ≤ 2.5 L·min(-1)×m(-2) (n = 39 each).
  
  
  RESULTS
  Compared with baseline level, LVEF increased [(31.56 ± 9.69)% vs. (28.44 ± 7.08)%, P < 0.01] at 24 h in both groups. LVEF increase at 24 h was similar between two groups [(3.11 ± 6.90)% vs. (3.00 ± 6.63)%, P > 0.05]. The PCWP decrease at 24 h was significantly greater in levosimendan group than in dobutamine group [(-8.90 ± 7.14) mm Hg vs. (-5.64 ± 6.83) mm Hg, P = 0.04]. Decrease in NT-proBNP at 3 days was also more significant in levosimendan group than in dobutamine group [the percentage change compared to baseline: (-22.36 ± 38.98)% vs. (-8.56 ± 42.42)%, P < 0.01]. Dyspnea improvement at 24 h was more significant in levosimendan group than in dobutamine group. The incidences of adverse reactions and events were similar between two groups.
  
  
  CONCLUSIONS
  LVEF improvement is similar between dobutamine and domestic levosimendan while greater decreases in PCWP and NT-proBNP are achieved with domestic levosimendan in patients with ADHF.
authors.affiliation: Department of Cardiology, Chinese Academy of Medical Sciences, Beijing, China.
authors.forename: Yu-hui
authors.initials: YH
authors.lastname: Zhang
authors.forename: Jian
authors.initials: J
authors.lastname: Zhang
authors.forename: En-ming
authors.initials: EM
authors.lastname: Qing
authors.forename: Hui
authors.initials: H
authors.lastname: Li
authors.forename: Ying-xian
authors.initials: YX
authors.lastname: Sun
authors.forename: Lin
authors.initials: L
authors.lastname: Zhang
authors.forename: Xiao-juan
authors.initials: XJ
authors.lastname: Bai
authors.forename: Wen-xian
authors.initials: WX
authors.lastname: Liu
authors.forename: Yi-nong
authors.initials: YN
authors.lastname: Jiang
authors.forename: Peng
authors.initials: P
authors.lastname: Qu
authors.forename: Bing-qi
authors.initials: BQ
authors.lastname: Wei
authors.forename: Qiong
authors.initials: Q
authors.lastname: Zhou
authors.forename: Yan
authors.initials: Y
authors.lastname: Huang
mesh_terms: D000368:Aged; D004280:Dobutamine / Q000627:therapeutic use*; D005260:Female; D006333:Heart Failure / Q000188:drug therapy*; D006801:Humans; D006835:Hydrazones / Q000627:therapeutic use*; D008297:Male; D008875:Middle Aged; D011724:Pyridazines / Q000627:therapeutic use*; D000077464:Simendan; D016896:Treatment Outcome
chemical_list: D006835:Hydrazones; D011724:Pyridazines; D000077464:Simendan; D004280:Dobutamine